| vTv Therapeutics is a holding company. Through its subsidiary, vTv Therapeutics LLC, Co. is a clinical stage biopharmaceutical company focused on the development of orally administered treatments for diabetes. Co. has a pipeline of small molecule clinical and pre-clinical drug candidates. Co.'s primary program is TTP399, an orally administered, small molecule, liver-selective glucokinase activator for the treatment of type 1 diabetes. In addition to the studies of TTP399, Co. is conducting a Phase 1 mechanistic study of TTP399 in patients with type 1 diabetes to determine the impact of TTP399 on ketone body formation during a period of acute insulin withdrawal. We show 30 historical shares outstanding datapoints in our coverage of VTVT's shares outstanding history.|
Understanding the changing numbers of VTVT shares outstanding — and
comprehending the concept of differing number of shares outstanding in general comparing companies like VTVT versus peers —
is critical for investors. Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies.
Furthermore, via issuance of new shares over time, or the repurchase of existing shares, the number of shares outstanding can fluctuate over the course of history.
With this page we aim to empower investors researching VTVT by allowing them to research VTVT shares outstanding history
as well as any other stock in our coverage universe.